EPAZ yields 7692.31% · JNJ yields 2.13%● Live data
📍 EPAZ pulled ahead of the other in Year 1
Combined, EPAZ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EPAZ + JNJ for your $10,000?
Epazz, Inc., together with its subsidiaries, designs and sells various software programs to business enterprises, hospitals, and government and post-secondary institutions in the United States. It offers EPAZZ BoxesOS v3.0, a Web portal infrastructure operating system that integrates with each organization's back-end systems and provides a customizable personal information system for various stakeholders, including students, faculty, alumni, employees, and clients. The company also provides AutoHire software, an interactive question, and online screening and ranking system; and Desk Flex software that allow businesses make use of office space restrictions by enabling employees to instantly access their workstation tools from various areas in and outside of the office. In addition, it offers Agent Power software, which provides information and tools for call centers to help enhance their workforce management; Integrated Plant Management Control software, a software system design for water and wastewater facility management; and CHMCi, an enterprise solution that includes tools to provide, manage, bill, and track behavioral healthcare and social services. Further, the company provides K9 Bytes, a point of sale (POS) software for pet care applications, such as pet boarding; daycare; grooming; training; and other pet care services, including dog walking and pet sitting. Its K9 Bytes products include scheduling, billing, retail inventory, and general POS capabilities comprising credit and debit card processing, collar printers, digital signature tablets, and biometric/fingerprint identification hardware. Epazz, Inc. was founded in 2000 and is headquartered in Chicago, Illinois.
Full EPAZ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.